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Objectives: Genome-wide association studies (GWAS) have identified >100 loci independently contributing to type 2 diabetes (T2D) risk.
However, translational implications for precision medicine and for the development of novel treatments have been disappointing, due to poor
knowledge of how these loci impact T2D pathophysiology. Here, we aimed to measure the expression of genes located nearby T2D associated
signals and to assess their effect on insulin secretion from pancreatic beta cells.
Methods: The expression of 104 candidate T2D susceptibility genes was measured in a human multi-tissue panel, through PCR-free expression
assay. The effects of the knockdown of beta-cell enriched genes were next investigated on insulin secretion from the human EndoC-bH1 beta-cell
line. Finally, we performed RNA-sequencing (RNA-seq) so as to assess the pathways affected by the knockdown of the new genes impacting
insulin secretion from EndoC-bH1, and we analyzed the expression of the new genes in mouse models with altered pancreatic beta-cell function.
Results: We found that the candidate T2D susceptibility genes’ expression is significantly enriched in pancreatic beta cells obtained by laser
capture microdissection or sorted by flow cytometry and in EndoC-bH1 cells, but not in insulin sensitive tissues. Furthermore, the knockdown of
seven T2D-susceptibility genes (CDKN2A, GCK, HNF4A, KCNK16, SLC30A8, TBC1D4, and TCF19) with already known expression and/or function
in beta cells changed insulin secretion, supporting our functional approach. We showed first evidence for a role in insulin secretion of four
candidate T2D-susceptibility genes (PRC1, SRR, ZFAND3, and ZFAND6) with no previous knowledge of presence and function in beta cells. RNA-
seq in EndoC-bH1 cells with decreased expression of PRC1, SRR, ZFAND6, or ZFAND3 identified specific gene networks related to T2D
pathophysiology. Finally, a positive correlation between the expression of Ins2 and the expression of Prc1, Srr, Zfand6, and Zfand3 was found in
mouse pancreatic islets with altered beta-cell function.
Conclusions: This study showed the ability of post-GWAS functional studies to identify new genes and pathways involved in human pancreatic
beta-cell function and in T2D pathophysiology.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original Article1. INTRODUCTION
Type 2 diabetes (T2D) is a complex, multifactorial disorder with an
estimated heritability ranging between 40% and 70% [1]. Genetic
studies have identified 28 genes causing monogenic diabetes due to
impaired insulin secretion. These genes are critically important for
pancreatic beta-cell lineage, phenotype, and function [1]. Genome-
wide association studies (GWAS) have shown that common T2D is
highly polygenic, with more than 100 loci contributing to T2D risk.
GWAS of related quantitative traits have shown that a significant part of
the T2D-associated single nucleotide polymorphisms (SNPs) also
modulates fasting plasma glucose levels and the homeostatic model
assessment (HOMA) of beta-cell function in non-diabetic individuals,
suggesting that their main diabetogenic impact was on insulin
secretion and not on insulin resistance [2]. Surprisingly indeed, only a
few T2D-associated SNPs were found to have an effect on fasting
serum insulin levels, the HOMA of insulin resistance, or the insulin
sensitivity index in general populations. About half of the T2D sus-
ceptibility SNPs did not have any apparent effect on glucose homeo-
stasis in non-diabetics [2].
Elucidating the function of T2D-associated SNPs (and target genes)
and their involvement in T2D pathophysiology may have major
translational implications for precision medicine and for the develop-
ment of novel treatments. Post-GWAS studies are challenging due to
the fact that the vast majority of these SNPs are non-coding and often
intergenic, which has not facilitated functional investigations of genes
located in these chromosome regions. In this context, a recent study
has demonstrated that T2D-associated SNPs are significantly enriched
in clusters of enhancers that are active in human pancreatic islets, and
most of these enhancers map less than 500 kb from transcription start
sites (TSS) of nearby genes [3]. Moreover, it has been recently shown
that most genes located nearby loci associated with blood pressure
(systolic, diastolic, pulse pressure) are highly expressed in vascular
tissues [4]. These data suggested that focusing the expression studies
and functional investigations on genes nearby GWAS-identified SNPs
may be a good first strategy, as they may drive pathways involved in
disease pathophysiology.
Here, we aimed to identify novel genes contributing to T2D risk through
a dominant effect on insulin secretion in human. To do so, we first
performed a comprehensive expression study of candidate T2D sus-
ceptibility genes closest to all GWAS-identified T2D SNPs in a large
panel of human organs, tissues, and cells, followed by the functional
analysis of the knockdown of these genes in human pancreatic beta-
cell lines. Using this strategy, we first found that the expression of
tested candidate T2D susceptibility genes was significantly and spe-
cifically enriched in pancreatic beta cells, and we reported functional
evidence for a role in insulin secretion of four T2D susceptibility genes
(PRC1, SRR, ZFAND3, and ZFAND6) with previously unknown presence
and function in pancreatic beta cells.
2. MATERIAL AND METHODS
2.1. Samples included in the panel expression study
Total RNA from human colon, liver, kidney, adipose tissue, lung,
skeletal muscle, heart, brain, small intestine, substantia nigra, hip-
pocampus, dorsal root ganglion, and insula, and Poly A þ RNA from
human hypothalamus, pituitary gland, caudate nucleus, and frontal
lobe were purchased from Clontech Laboratories (Palo Alto, CA, USA).
Pancreatic islets (n ¼ 8; average purity: 70.0%; average viability:
94.3%) and exocrine pancreas (n ¼ 2) were isolated from adult brain-
dead donors without diabetes, in accordance with French and Italian460 MOLECULAR METABOLISM 6 (2017) 459e470  2017 The Authors. Published by Elsevier GmbH. Thilocal ethics committee approval [5,6]. Pancreatic beta cells were ob-
tained by laser capture microdissection (LCM beta cells; n ¼ 2) [7] or
were sorted by flow cytometry (FACS sorted beta cells; n ¼ 5), as
previously described [8]. Primary pre-adipocytes (Lonza, Basel,
Switzerland) came from subcutaneous fat of a non-diabetic Caucasian
female patient. These pre-adipocytes were differentiated into mature
adipocytes in PBM-2 medium supplemented with insulin, dexameth-
asone, phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
(IBMX), and indomethacin (all supplied by Lonza) for 10 days ac-
cording to the manufacturer’s recommendations. RNA samples from
human EndoC-bH1 cells (n ¼ 3), pre-adipocytes, and mature adipo-
cytes were extracted as described below (see Section 2.9).
2.2. Probe design and selection for the panel expression study
Capture probes (containing a biotin affinity tag) and reporter probes
(containing a color-coded molecular barcode) were designed to detect
148 targets, including five housekeeping genes for normalization,
genes whose expression is known to be enriched (‘markers’) in
pancreatic islet including beta cell (n ¼ 13), gut (n ¼ 3), kidney
(n ¼ 4), lung (n ¼ 3), and adipose tissue (n ¼ 3), 28 genes known to
be involved in monogenic diabetes, and 104 genes located nearby
GWAS-identified SNPs associated with T2D risk (Table A) [1]. The
expression of the present housekeeping genes was previously shown
to be uniform across a large panel of human tissues using RNA-
sequencing (RNA-seq) [9]. Here, we found that the expression of the
five housekeeping genes was highly correlated across the present
panel of human tissues (R2> 0.85). The genes for which expression is
known to be enriched in specific tissues were chosen according to the
literature, the GTEx portal [10] and/or the BioGPS portal [11].
2.3. Panel gene expression study and statistical analysis
The detection of transcripts was carried out in multiplexed hybridiza-
tion reactions using NanoString Technologies (Seattle, WA, USA),
following manufacturer’s protocol. Each hybridization reaction con-
tained 25e100 ng total RNA or 5 ng Poly A þ RNA at a final con-
centration of 0.8e3.3 ng/ul and 0.16 ng/ul respectively. Reagents
were mixed and incubated at 65 C in a thermocycler block with a
heated lid for 16 h. All post-hybridization steps were handled roboti-
cally on a custom liquid-handling robot (Prep Station, NanoString
Technologies). Finally, samples were loaded into a microfluidic
chamber (nCounter Cartridge, NanoString Technologies) and imaged in
a Digital Analyzer (NanoString Technologies). Barcodes were counted
in 555 fields of view per sample. Experimental quality control was
performed with nSolver (NanoString Technologies) to flag failed
samples. Normalized expression values were first obtained by
considering the logarithm of the ratio of the expression of a given gene
over the average expression of the set of five housekeeping genes
(Table A) in corresponding samples. The expression profiles of relevant
gene sets were analyzed through heat map representations. A double
hierarchical clustering of the tissues and gene expressions in each set
was performed, using Ward’s method. Log2 expression was centered
and scaled. Each cell was colored to quantitatively reflect the relative
expression: from green if the gene is over-expressed in the tissue
compared to all other tissues, to red otherwise. For enrichment ana-
lyses, we established an expression threshold to classify ‘under-
expressed’ and ‘over-expressed’ sets of genes (i.e. genes involved in
monogenic diabetes, candidate susceptibility genes for T2D, and the
different markers) in each panel tissue. For this purpose, the threshold
was defined as the average gene expression across all tissues, plus
1.5 standard deviation (SD). We built a contingency table to count the
number of genes from each set that were under- and over-expresseds is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in the tested tissue and in the rest of the panel tissues. Fisher’s exact
test was applied to test whether the gene set was significantly over-
expressed in each tested tissue from the panel.
2.4. Culture of EndoC-bH1 cells
EndoC-bH1 cells [12] were cultured in low-glucose (5.6 mM) Dul-
becco’s modified Eagle’s medium (SigmaeAldrich, St. Louis, MO,
USA) with 2% BSA fraction V (Roche Diagnostics, Basel, Switzerland),
50 mM 2-mercaptoethanol, 10 mM nicotinamide (Calbiochem, Merck
Millipore, Billerica, MA, USA), 5.5 mg/ml human transferrin (Sigmae
Aldrich), 6.7 ng/ml sodium selenite (SigmaeAldrich), 100 U/ml peni-
cillin, and 100 mg/ml streptomycin (Life Technologies, Carlsbad, CA,
USA). Cells were seeded at a density of 2.5  106 on Matrigel (1%)/
fibronectin (2 mg/ml; SigmaeAldrich) coated plates and cultured at
37 C and 5% CO2.
2.5. Transfection of siRNA into EndoC-bH1 cells
SiRNA were transfected into EndoC-bH1 cells using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA). Freshly trypsinized EndoC-bH1
(1.5  106 cells) were incubated in suspension with Lipofectamine-
siRNA complex in Opti-MEM (Invitrogen) for 10 min and then were
plated onto Matrigel-fibronectin-coated culture wells. Six hours later,
the medium was replaced. We used ON-TARGETplus siRNA SMART-
pool for each gene (20e30 nM) and ON-TARGETplus nontargeting pool
for controls (siNTP; Dharmacon, Thermo Fisher Scientific, Waltham,
MA, USA). Cells were analyzed 72 h post transfection.
2.6. Assessment of insulin secretion from EndoC-bH1 cells
Transfected EndoC-bH1 cells were seeded onto Matrigel-fibronectin-
coated 96-well plates at 5  104 cells/well. Three days post trans-
fection, cells were incubated overnight in culture medium that con-
tained 2.8 mM glucose and then in HEPES-buffered KrebseRinger
Buffer (KRB; 116 mmol/l NaCl, 5.06 mmol/l KCl, 1.007 mmol/l CaCl2,
1.01 mmol/l MgCl2, 23.96 mmol/l NaHCO3, 10 mmol/l HEPES, pH 7.4,
and 0.2% BSA solution) that contained 0.5 mM glucose  0.5 mM
IBMX (Sigma Aldrich) for 60 min. This supernatant was subsequently
collected (supernatant 1) and replaced with 16.7 mM glucose
KRB  0.5 mM IBMX for 60 min at 37 C and then collected (su-
pernatant 2). For insulin content measurement, cells were lysed with
TETG buffer (20 mM TriseHCl pH 8.0, 137 mM NaCl, 1% Triton X-100,
10% Glycerol, 2 mM EGTA with protease inhibitors; Roche). Lysate and
supernatants were centrifuged for 5 min at 700 g. Samples were kept
frozen at20 C before use. Insulin concentration in the supernatants
and intracellular content of the EndoC-bH1 cells were measured by
ELISA according to manufacturer’s instructions using the Human In-
sulin Kit (Mercodia, Uppsala, Sweden). Insulin content was used for
normalization.
2.7. Statistical analysis of insulin secretion from EndoC-bH1 cells
Absorbance data were measured, with technical duplicates of exper-
imental triplicates, leading to six measurements maximum per
experimental conditions (that were subsequently repeated). To ensure
a reduced technical bias from the absorbance data, the technical
duplicates’ average absorbance was kept when the relative error was
lower than 20% among the technical duplicates (this threshold being
based on the observed distribution of the technical relative errors over
100 experiments). Fold changes of insulin secretion (i.e. secretion at
stimulatory glucose levels divided by secretion at basal glucose levels)
were then computed for each siRNA. Fold change of insulin secretion
for each siRNA was analyzed using a linear regression adjusted for
experimental conditions (operator and date).MOLECULAR METABOLISM 6 (2017) 459e470  2017 The Authors. Published by Elsevier GmbH. This is an op
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Cell viability was measured by quantifying the amount of ATP present,
which indicates the presence of metabolically active cells, through the
CellTiter-Glo 2.0 Assay (Promega, Madison, WI, USA), following
manufacturer’s protocol. Luminescence measurement was performed
at baseline and 72 h after transfection of siRNA.
2.9. Mice and mouse islet isolation
Control female C57BL/6J mice and obese (ob/ob) female mice of the
C57BL/6J background were obtained from Elevage Janvier (Le Genest-
Saint-Isle, France). Isolation and islet cultures were performed as
previously described [13]. Briefly, mouse islets were maintained in
islets medium (RPMI 1640; GIBCO Life Technologies) with serum (FCS;
PAA laboratories, GE Healthcare, Velizy-Villacoublay, France), 1 mM
sodium pyruvate, 50 mM b-mercaptoethanol, 10 mM Hepes and
100 U/ml penicillin, and 100 mg/ml streptomycin (Life Technologies).
For the streptozotocin (STZ) treated islets (from control mice), 2 mM of
Streptozocin Sigma S0130 (SigmaeAldrich) were added in the islet
medium for 24 h. All animal procedures were conducted in accordance
with the institutional guidelines approved by the institutional Animal
Care and Ethical Use Committee of the University of Lille, France.
2.10. RNA isolation, reverse transcription, and quantitative RT-PCR
Total RNA was extracted 72 h post transfection from EndoC-bH1 cell
using the NucleoSpin RNA II kit (MachereyeNagel, Düren, Germany)
following the manufacturer’s instructions. Total RNA from mouse
pancreatic islets was extracted using the RNeasy Mini Kit (Qiagen,
Courtabœuf, France).
The assessment of purity and quantity of extracted RNA was performed
using NanoDrop 2000 spectrophotometer (Thermo Fisher). cDNA was
synthetized from 400 ng of total RNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions.
RT-qPCR was performed using Brilliant III QRT-PCR SYBR Green Low
ROX Master Mix (Agilent, Santa Clara, CA, USA) and was analyzed
through the ViiA 7 Real-Time PCR System (Applied Biosystems).
Knockdown efficiency was assessed by RT-qPCR of the target genes
using the following PrimeTime qPCR Primers or designed primers
(Integrated DNA Technologies): ZFAND3 (Hs.PT.58.1283673),
ZFAND6 (Hs.PT.58.14433903), PRC1 (Hs.PT.58.50434811), SRR
(Hs.PT.58.25800883), KCNK16 (Hs.PT.58.20909681), CDKN2A
(Hs.PT.58.40743463g), SLC30A8 (Hs.PT.56a.14618432), TBC1D4
(Hs.PT.58.45499), TCF19 (Hs.PT.58.23138597), HNF4A (Forward: 50-
GCC ATC ATC TTC TTT GAC CCA-30; Reverse: 50-GAT GTA GTC CTC
CAA GCT CAC-30), GCK (Forward: 50-TGA AGG TGG GAG AAG
GTG AG-30; Reverse: 50-GAT GCA CTC AGA GAT GTA GTC G-30),
MPHOSPH9 (Hs.PT.58.3849657), SSR1 (Hs.PT.58.2437881), FAF1
(Hs.PT.58.39097947), KLHDC5 (Hs.PT.58.21065180), in triplicate
on 384-well plates. PSMB2 (Forward: 50-TTG TCC AGA TGA AGG ACG
ATC A-30; Reverse: 50-AGC CTC TCC AAC ACA CAG GA-30)
endogenous control gene was used to normalize gene expression by
DDCt method, where the final normalized quantity was expressed as
2(Ct target e Ct siNTP). For the gene expression study in mouse pancreatic
islets, we followed the same methods and used the following primers:
Prc1 (Forward: 50-AGC CTG TGG AGG CAA TTATG-30; Reverse: 50-AAC
CGT ACA ATC TCG GCA TC-30), Srr (Forward: 50-CCT GCA GTG ATA GCT
GGA CA-30; Reverse: 50-AAG CCA ATG CTG GAT TTG AC-30), Zfand3
(Forward: 50-GGG GTC CAG CAA GAC TAT GA-30; Reverse: 50-CTA CTA
GTC GCG GTC GCT TC-30), Zfand6 (Forward: 50-GAG ACA GAA GAC CTG
CAA GGA-30; Reverse: 50- ACG GTG CAC ACC ACA GTA AA-30) and Ins2
(Forward: 50-TCT AGT TGC AGT AGT TCT CCA-30; Reverse: 50-TGG CTTen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 461
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AGC AAG-30; Reverse: 50-AGC TCA GTA ACA GTC CGC C-30) endoge-
nous control gene was used to normalize gene expression.
2.11. RNA-seq
RNA-seq was performed in RNA samples that were extracted from
EndoC-bH1 cells transfected with either siNTP, siPRC1, siSRR, siZ-
FAND6, or siZFAND3, from at least three independent transfections.
RNA libraries were prepared using the TruSeq Stranded mRNA Library
Preparation Kit (Illumina, San Diego, CA, USA) following the manu-
facturer’s instructions. The libraries were sequenced using the HiSeq
4000 (Illumina). A mean of 65 million paired-end reads of 75 bp were
generated for each sample. More than 90% of the reads for each li-
brary were effectively mapped to the hg19 human genome assembly
using TopHat2 [14]. Subsequently, both quantification and annotation
of the reads were performed using Bioconductor package Rsubread
[15]. Finally, the differential gene expression analyses (i.e. EndoC-bH1
cells transfected with siNTP versus EndoC-bH1 cells transfected with
either siPRC1, siSRR, siZFAND6, or siZFAND3) were performed using
Bioconductor package DESeq2 [16]. The differentially expressed
genes were subjected to Ingenuity Pathway Analysis (Qiagen, Hilden,
Germany) to decipher the major biological pathways, networks, and
diseases emphasized by the significantly deregulated genes (with a
p-value < 0.05).
2.12. Immunofluorescence
Isolated human islet clusters or tissue sections from normal human
pancreases were collected and fixed in 4% (v/v) paraformaldehyde
overnight. Before immunofluorescence, sections were deparaffinized
with xylene and rehydrated with a series of alcohol solutions of
decreasing concentration (90e70e50%). Sections and cells attached
to chambers were then washed with PBS. Antibody dilutions and
rinsing steps were performed in PBS. Incubations with primary anti-
bodies were done at 4 C overnight. For double staining, slides were
pre-treated 20 min with 0.5% Triton X-100 and 30 min with 0.1% BSA
at room temperature. Slides were then incubated with a guinea pig
anti-insulin antibody (1:500; Abcam, Cambridge, UK) and either rabbit
anti-PRC1 (1:100; Abcam), rabbit anti-SRR (1:100; Abcam), rabbit anti-
ZFAND3 (1:100; Novus Biologicals, Littleton, CO, USA), or rabbit anti-
ZFAND6 (1:100; Novus Biologicals) antibodies. After rinsing with PBS,
slides were incubated for 1 h with either an Alexa fluor 594-conjugated
anti-guinea antibody (1:500; Thermo Fisher Scientific) or Alexa fluor
488-conjugated anti-rabbit antibody (1:500; Thermo Fisher Scientific).
For immunofluorescence of EndoC-bH1 cells, after blocking with PBS
5% BSA for 30 min, cells were incubated with the primary antibodies
for 1 h. Immunofluorescence staining in tissue sections from normal
human pancreases was performed when the immunofluorescence
staining in isolated human islet clusters was not clear enough.
3. RESULTS
3.1. Expression of candidate T2D susceptibility genes in a large
panel of human organs, tissues, and cells
We analyzed the expression profile of 104 candidate T2D susceptibility
genes (Table A) located nearby GWAS-identified SNPs associated with
T2D risk [1] in a panel of human organs, tissues, and cells including
colon, small intestine, liver, kidney, adipose tissue, pre-adipocytes,
mature adipocytes, lung, skeletal muscle, heart, whole brain, sub-
stantia nigra, hippocampus, insula, hypothalamus, pituitary gland,
caudate nucleus, frontal lobe, dorsal root ganglion, pancreatic islets,
LCM beta cells, FACS sorted beta cells, exocrine pancreas, and the462 MOLECULAR METABOLISM 6 (2017) 459e470  2017 The Authors. Published by Elsevier GmbH. Thihuman pancreatic beta-cell line EndoC-bH1 [12]. For this purpose, we
used the PCR-free NanoString technology enabling the count of
messenger RNA molecules without any biases due to amplification
step. The heat map representation reporting the expression profile of
104 candidate susceptibility genes for T2D in the panel of human
tissues is shown in Figure A.
In order to validate this methodology, we first explored in the same panel
of human samples the expression of genes (i.e. ‘markers’) known to be
highly (or even specifically) expressed in the gut (Figure B1), adipose
tissue (Figure C1), kidney (Figure D1), lung (Figure E1), and pancreatic
islet (Figure F1). Furthermore, we investigated the expression of 28
genes known to be involved in monogenic diabetes (Figure G), as the
proteins encoded by these genes have a well-known role in the function
and/or development of pancreatic beta cells [1]. As expected, we
confirmed a significant enrichment of our gut markers expression in
small intestine (p¼ 6.7 105; Figure B2), of adipose tissue markers
expression in mature adipocytes and adipose tissue (p ¼ 3.4  104;
and p ¼ 3.4  104, respectively; Figure C2), of kidney markers
expression in kidney (p¼ 1.5 106; Figure D2), and of lung markers
expression in lung (p¼ 1.7 105; Figure E2). Importantly, we found
that the expression of the pancreatic islet markers is significantly
enriched in pancreatic islets, FACS sorted beta cells, LCM beta cells,
and EndoC-bH1 cells (p ¼ 2.3  104; p ¼ 1.9  105;
p¼ 2.3 1011; and p¼ 5.0 108, respectively; Figure F2), but is
not significantly enriched in exocrine pancreas (p > 0.05; Figure F2).
Secondly, we found that the expression of the genes causing mono-
genic diabetes is significantly enriched in LCM beta cells, FACS sorted
beta cells and EndoC-bH1 cells (p ¼ 2.1  103; p ¼ 2.1  103;
and p ¼ 3.0  104, respectively; Figure 1). Altogether these results
validated the accuracy of our methodology.
Interestingly, the expression of the 104 candidate T2D susceptibility
genes was also significantly enriched in LCM beta cells, FACS sorted
beta cells and EndoC-bH1 cells (p ¼ 5.1  104; p ¼ 1.6  103;
and p ¼ 1.6  103, respectively; Figure 2), but not in the main
insulin-target tissues including liver, adipose tissue, or skeletal muscle
(p > 0.05; Figure 2).
3.2. Effect of candidate T2D susceptibility genes knockdown on
insulin secretion from human EndoC-bH1 cells
Our present expression results prompted us to investigate the effect of
candidate T2D susceptibility gene knockdown by siRNA on insulin
secretion from human pancreatic EndoC-bH1 beta-cell line. We
selected genes to be silenced based on at least one of these two
criteria: i) a high expression in EndoC-bH1 cells, and/or ii) an enriched
expression in EndoC-bH1 cells compared to all non-pancreatic tissues.
We subsequently obtained 15 genes in which decreased expression by
siRNA in EndoC-bH1 cells was above 50% (Figure H). Among these
genes, there were GCK encoding glucokinase and HNF4A encoding
hepatocyte nuclear factor 4 alpha. These two genes are known to be
mutated in patients presenting with monogenic diabetes and to play a
key role in insulin secretion from pancreatic beta cells [1]. Further-
more, mice with either a global Gck deletion or beta cell-specific Gck
deletion die within a few days of birth from severe hyperglycemia [17];
mice with beta cell-specific Hnf4a deletion exhibit impairment of
glucose-stimulated insulin secretion (GSIS) [18]. Therefore, we ex-
pected that the decreased expression of GCK or HNFA4 also would
have significantly impaired insulin secretion from EndoC-bH1 cells. We
found that the decreased expression of HNF4A significantly reduces
glucose-stimulated insulin secretion (GSIS; p < 0.01, Figure 3A), and
GCK knockdown significantly decreases GSIS evoked by IBMX
(p < 0.001; Figure 3B). These results validated our protocol.s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Enrichment analysis of the expression of the genes causing monogenic diabetes in the panel of human organs, tissues, and cells. The black vertical line
denotes a p-value of 0.05.We did not find any significant effect of the decreased beta-cell
expression of MPHOSPH9, SSR1, FAF1 or KLHDC5 on GSIS evoked
or not by IBMX (p > 0.05; Figure I1eI4, respectively).
In contrast, insulin secretion from EndoC-bH1 cells was signifi-
cantly changed by the decreased expression of five T2D suscep-
tibility genes already suggested to be expressed and/or to
contribute to beta-cell function [19e23]: the knockdown of TCF19
was found to significantly decrease GSIS (p < 0.01; Figure 4A); the
decreased expression of SLC30A8 affected GSIS evoked or not by
IBMX (p < 0.05; Figure 4B); the knockdown of TBC1D4 was found
to significantly reduce GSIS evoked by IBMX (p < 0.01; Figure 4C);
the decreased expression of CDKN2A was found to decrease GSISFigure 2: Enrichment analysis of the expression of candidate T2D-susceptibility gen
p-value of 0.05.
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KCNK16 was found to stimulate GSIS evoked by IBMX (p < 0.05;
Figure 4E).
Furthermore, we found that the decreased expression of four other
candidate T2D susceptibility genes, with no evidence of expression
and role in beta cells, significantly affects insulin secretion from
EndoC-bH1 cells: the PRC1 knockdown was found to significantly
reduce GSIS evoked or not by IBMX (p < 0.05; Figure 5A); the SRR
knockdown was found to significantly decrease GSIS evoked by IBMX
(p < 0.01; Figure 5B); the ZFAND3 knockdown was found to signifi-
cantly affect GSIS (p < 0.01; Figure 5C); and the ZFAND6 knockdown
was found to reduce GSIS evoked by IBMX (p < 0.05; Figure 5D).es in the panel of human organs, tissues, and cells. The black vertical line denotes a
en access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 463
Figure 3: Decreased expression of HNF4A (A) or GCK (B), causing monogenic diabetes, leads to impaired insulin secretion from EndoC-bH1 cells. EndoC-bH1 cells were
transfected with control non-targeting pool siRNA (siNTP) or target gene siRNA and were analyzed 72 h post-transfection. Insulin secretion (percentage of secretion of the total
insulin content) was analyzed in response to 60 min incubation with 0.5 mM glucose (0.5 mM IBMX), followed by 60 min incubation with 16.7 mM glucose (0.5 mM IBMX).
Data represent mean values  SEM of at least three independent experiments. **p < 0.01; ***p < 0.001; ns, not significant. Glc, glucose; IBMX, phosphodiesterase inhibitor
3-isobutyl-1-methylxanthine.
Original ArticleAs PRC1 (encoding protein regulator of cytokinesis 1), SRR (encoding
serine racemase), ZFAND3 (encoding zinc finger AN1-type containing
3), and ZFAND6 (encoding zinc finger AN1-type containing 6) have
never been described in pancreatic islets and beta cells, we confirmed
their expression at protein level by immunofluorescence staining in
human pancreatic islets (Figure 6AeD, J1 and J2) and in EndoC-bH1
cells (Figure K1eK4).
3.3. Deciphering the major biological pathways and networks
emphasized by the decreased expression of PRC1, SRR, ZFAND6,
and ZFAND3 in EndoC-bH1 cells
We next performed RNA-seq in EndoC-bH1 cells with decreased
expression of PRC1, SRR, ZFAND6, or ZFAND3, compared to control
cells, to decipher themajor biological pathways and networks associated
with those genes with yet unknown function in pancreatic beta cells.
When we analyzed the transcriptome of EndoC-bH1 cells transfected
with siPRC1 versus the transcriptome of control cells using Ingenuity464 MOLECULAR METABOLISM 6 (2017) 459e470  2017 The Authors. Published by Elsevier GmbH. ThiPathway Analysis (IPA), we found that PRC1 was included in a network
of 28 molecules entitled “Cell Cycle, Cellular Movement, Cellular As-
sembly and Organization” (Figure L1). Subsequently, we analyzed the
diseases and/or functions emphasized by the PRC1 knockdown in
EndoC-bH1 cells. Among the significant outputs, we found networks
related to the “quantity of carbohydrates” (p¼ 2.7 108; Figure L2),
“quantity of insulin in blood” (p ¼ 4.8  105; Figure L3), or “con-
centration of D-glucose” (p¼ 4.6 108; Figure L4). Furthermore, we
found a network related to “apoptosis” (p ¼ 1.1  104; Table B), in
particular “apoptosis of islets of Langerhans” (p ¼ 4.3  103;
Figure 7A), and a network related to “quantity of pancreatic cells”
(p ¼ 9.9  104; Figure 7B). When we analyzed the viability of the
EndoC-bH1 cells transfected with siPRC1 compared to control cells,
we found that PRC1 knockdown significantly decreased the viability of
EndoC-bH1 cells (p ¼ 1.4  106; Figure 7C).
When we analyzed the diseases and/or functions emphasized by the
SRR knockdown in EndoC-bH1 cells, we found a significant networks is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Decreased expression of TCF19 (A), SLC30A8 (B), TBC1D4 (C), CDKN2A (D), or KCNK16 (E), already suggested to be expressed in beta cell and/or to
contribute to beta-cell function, significantly modifies insulin secretion from EndoC-bH1 cells. EndoC-bH1 cells were transfected with control non-targeting pool siRNA
(siNTP) or target gene siRNA and were analyzed 72 h post-transfection. Insulin secretion (percentage of secretion of the total insulin content) was analyzed in response to 60 min
incubation with 0.5 mM glucose (0.5 mM IBMX), followed by 60 min incubation with 16.7 mM glucose (0.5 mM IBMX). Data represent mean values  SEM of at least three
independent experiments. *p < 0.05; **p < 0.01; ns, not significant. Glc, glucose; IBMX, phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine.related to “serine phosphorylation” (p ¼ 8.5  107; Figure M1), in
particular “serine phosphorylation of peptide” (p ¼ 6.3  107;
Figure M2), a network related to “endoplasmic reticulum stress
response” (p ¼ 8.9  103; Figure M3) and a network related to
“congenital disorders of glycosylation” (p ¼ 2.5  104;
Figure M4).
When we analyzed the transcriptome of EndoC-bH1 cells transfected
with siZFAND6 versus the transcriptome of control cells, we found that
ZFAND6 was included in a network of 27 molecules entitled “Cell
Signaling, Lipid Metabolism, Small Molecule Biochemistry”
(Figure N1). Furthermore, among the top diseases and/or functions
emphasized by the ZFAND6 knockdown in EndoC-bH1 cells, we found
significant networks related to “glycolysis” (p ¼ 8.0  103;MOLECULAR METABOLISM 6 (2017) 459e470  2017 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comFigure N2) and to “quantity of insulin in blood” (p ¼ 7.3  103;
Figure N3). We found a significant network related to “abnormal
morphology of pancreas” (p ¼ 2.2  103; Figure N4), in particular
“abnormal morphology of small islets of Langerhans”
(p ¼ 1.8  102; Figure N5).
We subsequently analyzed the transcriptome of EndoC-bH1 cells
transfected with siZFAND3 versus the transcriptome of control cells.
We found that ZFAND3 is included in a network of 16 molecules
entitled “Cellular Assembly and Organization, Lipid Metabolism, Mo-
lecular Transport” (Figure O1). Furthermore, among the top diseases
and/or functions emphasized by the ZFAND3 knockdown in EndoC-
bH1 cells, we found a significant network related to “transport of
alpha-amino acid” (p ¼ 8.9  104; Figure O2).en access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 465
Figure 5: Decreased expression of PRC1 (A), SRR (B), ZFAND3 (C), or ZFAND6 (D), with no evidence of expression and role in pancreatic beta cells, leads to impaired
insulin secretion from EndoC-bH1 cells. EndoC-bH1 cells were transfected with control non-targeting pool siRNA (siNTP) or target gene siRNA and were analyzed 72 h post-
transfection. Insulin secretion (percentage of secretion of the total insulin content) was analyzed in response to 60 min incubation with 0.5 mM glucose (0.5 mM IBMX), followed
by 60 min incubation with 16.7 mM glucose (0.5 mM IBMX). Data represent mean values  SEM of at least three independent experiments. *p < 0.05; **p < 0.01; ns, not
significant. Glc, glucose; IBMX, phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine.
Original Article3.4. Positive correlation between the expression of Ins2 and the
expression of Prc1, Srr, Zfand6, and Zfand3 in mouse pancreatic
islets with altered beta-cell function
We finally investigated the expression of the four genes in mouse
models with defective pancreatic beta-cell function due to STZ treat-
ment or with compensatory islet cell function in ob/ob mice carrying aFigure 6: PRC1 (A), SRR (B), ZFAND3 (C), and ZFAND6 (D) are expressed in human pa
for PRC1 (green; A), SRR (green; B), ZFAND3 (green; C), ZFAND6 (green, D), and insulin (red
localization of PRC1, SRR, ZFAND3, or ZFAND6 with insulin. Blue, DAPI.
466 MOLECULAR METABOLISM 6 (2017) 459e470  2017 The Authors. Published by Elsevier GmbH. Thinon-sense mutation in the leptin gene. In two pools of pancreatic islets
treated or not with STZ from eight 10-week old mice, we found a
strong positive correlation between the expression of Ins2 and the
expression of Prc1, Srr, Zfand3, and Zfand3: the expression of these
five genes was significantly reduced in pancreatic islets treated with
STZ (Figure P1 and P2). Furthermore, in pancreatic islets from fivencreatic islets and beta cells. Representative images of immunofluorescence staining
) performed on fixed isolated human islet clusters. Yellow (merged images) indicates co-
s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: Decreased PRC1 expression in EndoC-bH1 cells leads to increased apoptosis and decreased cell viability. List of deregulated genes emphasized by the
decreased expression of PRC1 in EndoC-bH1 cells within the network related to apoptosis of islets of Langerhans (A) and the quantity of pancreatic cells (B) through IPA. Cell
viability measurement (C) performed at baseline (100%) and 72 h post transfection of siRNA (% compared to baseline). Data at 72 h represent mean values  SEM of at least five
independent experiments. ***p < 0.001.5-week old mice or from five 8-week old mice, we also found this
positive correlation: the expression of Ins2, Prc1, Srr, Zfand3, and
Zfand6 was strongly increased in ob/ob mice when compared to
control mice (Figure P3 and P4).
4. DISCUSSION
4.1. Enrichment of GWAS-identified candidate T2D susceptibility
genes in human pancreatic beta cells
Our first objective was to select candidate genes for putative insulin
secretion defect associated with T2D from the list of genes closed to
GWAS-identified SNPs associated with T2D risk. During the course of
this analysis, we demonstrated that the expression of these 104 genes
was enriched in human pancreatic beta cells. Surprisingly perhaps, we
did not find any similar enrichment of their expression in insulin
sensitive skeletal muscle, liver, adipose tissue, and in the gut and
brain. An obvious limitation of our specific analysis is the fact that we
analyzed the expression of the genes closest to GWAS-identified T2D
SNPs, while one cannot rule out that a given T2D-associated SNP may
also impact expression of gene(s) located several megabases away
from the SNP, through a loop between a distal enhancer (where this
SNP maps) and the target gene promoter. However, the majority of
GWAS-identified T2D genes map in DNA sequences of enhancer
specifically active in human pancreatic islets, which are usually located
in the vicinity of the cis-regulated gene transcription start sites [3]. In
support of our result, when we assessed in the same panel of human
tissues the expression of candidate obesity susceptibility genes closed
to GWAS-identified obesity SNPs, we did not identify any enrichment of
gene expression in beta cells while we found significant enrichment of
gene expression in several regions of the brain (data not shown).
Therefore, we believe that our conclusion on the enrichment of theMOLECULAR METABOLISM 6 (2017) 459e470  2017 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comexpression of our selection of T2D genes in beta cells is not artefactual
and is probably representative of other T2D genes, if they exist.
4.2. Decreased expression of seven genes (GCK, HNF4A, TCF19,
SLC30A8, TBC1D4, CDKN2A, and KCNK16) already suggested to be
expressed in beta cells and/or to contribute to beta-cell function
significantly modifies insulin secretion from EndoC-bH1 cells
Subsequently, in the human EndoC-bH1 beta-cell line, we investigated
the effect on insulin secretion of the knockdown of the 15 T2D sus-
ceptibility genes with the highest and/or the most specific expression
in beta cells (with successful RNA interference). We first found that the
decreased expression of the seven genes that were already suggested
to be expressed and/or to contribute to beta-cell function (including
GCK, HNF4A, TCF19, SLC30A8, TBC1D4, CDKN2A and KCNK16) is
significantly associated with modified insulin secretion.
Indeed, as discussed above (Section 3.2), both GCK and HNF4A are
known to be mutated in patients presenting with monogenic diabetes
and to play a key role in insulin secretion from pancreatic beta cells [1].
TCF19 encodes the transcription factor 19 and has been reported to be
expressed in human pancreatic islets [21]. Furthermore, TCF19 was
found to be a transcription factor necessary for proliferation and sur-
vival in the rat pancreatic INS-1 beta-cell line [21]. Our data comple-
ment the current knowledge about this gene role, as we found that
TCF19 knockdown significantly decreased GSIS in human beta-cell
lines.
SLC30A8 encodes the solute carrier family 30 member 8, which is a
zinc transporter almost exclusively expressed in pancreatic alpha cells
and beta cells and involved in the accumulation of zinc within insulin or
glucagon secretory granules [24]. Here, we found that SLC30A8
knockdown significantly decreases GSIS in human beta cells. Impor-
tantly, this result was in line with previous data showing that theen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 467
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risk [25] was deleterious for SLC30A8 zinc transport activity [26,27].
Our data also supported previous results based on mice models which
showed that mice deleted for Slc30a8 present with significant im-
pairments in glucose tolerance and that, in contrast, transgenic mice
over-expressing Slc30a8 display improved glucose homeostasis [22].
However, our result did not support the hypothesis generated through
the sequencing or genotyping ofw150,000 individuals that suggested
that low-frequency loss-of-function mutations in SLC30A8 protect
against T2D [28]. In order to reconcile this apparent contradiction,
Rutter and Chimienti have recently suggested that the degrees of
overall inhibition of SLC30A8 activity might be different according to
the variant frequency, and that the resulting deleterious effect might be
dependent on age or hypoxic beta-cell stress [24]. Still, our data
showed that decreasing SLC30A8 expression by 70% in human beta
cells is apparently deleterious for insulin secretion.
TBC1D4 encodes the Tre-2/BUB2/CDC16 domain family member 4
that is a Rab-GTPase-activating protein. This protein has been actively
explored in skeletal muscle and adipose tissue and was found to play a
key role in insulin-stimulated glucose uptake in these metabolic tis-
sues [29]. Importantly, the GWAS-identified T2D-associated TBC1D4
SNP in Greenlandic individuals was shown to cause insulin resistance
in skeletal muscle [30]. However, this protein was also identified in
human and mouse pancreatic beta cells, and TBC1D4 mRNA
expression was found to be downregulated in pancreatic islets from
individuals with T2D [19]. Furthermore, Tbc1d4 knockdown by siRNA
strongly decreased GSIS from mouse pancreatic MIN6 beta-cell line
[19], which was in line with our present result in human EndoC-bH1
cells. In conclusion, our data on TBC1D4 have fully complemented
previous observational studies in human islets and experimental
studies in animal models and cell lines.
CDKN2A encodes the cyclin dependent kinase inhibitor 2A, also known
as the tumor suppressor protein P16-INK4A. Here, we found that
CDKN2A knockdown significantly decreases GSIS evoked by IBMX
from EndoC-bH1 cells. This result was inconsistent with a previous
study, which reported that CDKN2A knockdown significantly enhances
GSIS evoked by IBMX from the same cell model [31]. These opposite
results might be explained by the different experimental conditions. In
the present study, we performed a stimulation step (16.7 mM
glucose  IBMX) subsequent to basal incubation (0.5 mM
glucose  IBMX) in the same wells, while Pal and colleagues per-
formed static insulin secretion assays, namely basal incubation and
stimulation step were performed in different wells [31]. As EndoC-bH1
cells are not always sensitive to glucose, the static protocol may lead to
artefactual positive results. The same team did not confirm their re-
sults on CDKN2A knockdown in their recent systematic functional
screening of candidate T2D susceptibility genes in the same EndoC-
bH1 cells [32]. In support of our conclusions, mice beta-cell specific
activation of Cdkn2a enhanced GSIS, and increased Cdkn2a expres-
sion was found to be a marker of beta-cell senescence, associated
with enhanced GSIS during mice normal aging [20]. Importantly,
Helman and colleagues also showed that CDKN2A-induced senes-
cence in human EndoC-bH2 cells enhances GSIS [20]. Thus, we
believe from our data and others that decreased CDKN2A expression
probably decreases GSIS and increases T2D risk (and not the
opposite).
KCNK16 encodes the potassium two-pore domain channel subfamily K
member 16 (also known as TALK1). This channel was shown to be
expressed in mouse and human pancreatic beta cells and to play a key
role in cell electrical excitability and in GSIS [23]. The GWAS-identified
nonsynonymous SNP associated with increased T2D risk was found to468 MOLECULAR METABOLISM 6 (2017) 459e470  2017 The Authors. Published by Elsevier GmbH. Thienhance the channel activity, and Kcnk16 knockout in mouse beta
cells enhanced Ca2þ influx and second-phase GSIS [23], which was in
line with our present results in EndoC-bH1 cells demonstrating that
KCNK16 knockdown increases insulin secretion in humans.
4.3. Decreased expression of four genes (PRC1, SRR, ZFAND6, and
ZFAND3) with no evidence of expression and role in pancreatic beta
cells significantly modifies insulin secretion from EndoC-bH1 cells
We also found for the first time that the decreased expression of four
T2D susceptibility genes (PRC1, SRR, ZFAND6, and ZFAND3, respec-
tively), with no evidence of expression and role in beta cells, signifi-
cantly affects insulin secretion from human EndoC-bH1 cells. Although
PRC1, SRR, ZFAND6, and ZFAND3 were ubiquitously expressed ac-
cording to our panel of human tissues (Figure Q1eQ4, respectively)
and to the Genotype-Tissue Expression (GTEx) portal [10], they were
highly expressed and/or enriched in FACS sorted human beta-cells and
in EndoC-bH1. Furthermore, the investigation of mouse pancreatic
islets with altered beta-cell function demonstrated a positive correla-
tion between the expression of insulin and the expression of Prc1, Srr,
Zfand3, and Zfand6, confirming a role of these genes in pancreatic
beta-cell function.
4.3.1. PRC1, a new gene involved in beta-cell function
PRC1 is a key regulator of cytokinesis and involved in many cancers. In
hepatocellular carcinoma, PRC1 has an oncogenic effect through the
enhancement of cancer proliferation, metastasis, and tumorigenesis
[33]. Importantly, the GWAS-identified PRC1 SNP associated with T2D
risk was also found to contribute to breast cancer risk [34]. Our RNA-
seq data from EndoC-bH1 cells with PRC1 knockdown compared to
control human cell line identified a network of genes related to cell
cycle, cellular movement, cellular assembly and organization, as well
as other gene networks related to glucose homeostasis and two
networks related to apoptosis, especially one specific to pancreatic
islets. We believe these results based on next-generation sequencing
are sound as we found that PRC1 knockdown in EndoC-bH1 cells
significantly decreased their viability compared to control cells, which
validated our RNA-seq analyses.
4.3.2. SRR, a new gene involved in beta-cell function
SRR is an enzyme generating D-serine from L-serine that is an
endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor.
Adult mice deleted for Srr presented with schizophrenia-like behavioral
abnormalities, which could be rescued by D-serine administration [35].
Our RNA-seq data from EndoC-bH1 cells with SRR knockdown
compared to control EndoC-bH1 cells emphasized a network related to
serine phosphorylation (in particular serine phosphorylation of pep-
tides). Importantly, metabolomics studies have suggested that serine
predicted T2D incidence [36] and gestational diabetes mellitus inci-
dence [37]. Furthermore, the transcriptome of EndoC-bH1 cells with
SRR knockdown identified a network related to endoplasmic reticulum
stress response, which has been reported to be involved in decreased
insulin secretion and in T2D development [38]. Altogether, our data
emphasized the interest of serine metabolism in T2D and human beta
cells, opening potential avenues for prevention, in particular in high
risk populations such as women with history of gestational diabetes
mellitus.
4.3.3. ZFAND3 and ZFAND6, two new genes involved in beta-cell
function
Very little is known about ZFAND3 and ZFAND6. Interestingly, the
GWAS-identified SNP at ZFAND3 locus associated with T2D risk wass is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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precisely altering the related human islet enhancer activity bringing
mechanistic explanation of its functional impact [3].
4.4. Conclusion
In conclusion, our staged post-GWAS functional study has several
implications for further T2D pathophysiological investigations. First, it
demonstrated that the expression of candidate T2D susceptibility
genes closest to GWAS-identified T2D SNPs (usually named as T2D
genes by consortia) is strongly enriched in human beta cells. We
believe our study is useful for T2D pathophysiology, but we
acknowledge that our study was far from being exhaustive as we did
not, for feasibility reasons, systematically test the several hundreds of
genes located in the same topologically associating domain (TAD) as
GWAS-identified T2D SNPs, namely all genes that may, in theory, be
regulated by these SNPs (as located in the same regulatory loop).
Furthermore, we chose not to systematically test the genes located in
the so-called linkage disequilibrium (LD) blocks around T2D SNPs, as
regulatory regions are different from LD blocks that are only units of
similar genetic recombination. Nevertheless, our data provide original
information about the consequences of the partial inactivation of
analyzed T2D genes on human beta-cell function, which contribute to
the elucidation of conflicting functional data obtained for some T2D
genes such as SLC30A8 or CDKN2A. We agree that further validation in
human mature islets would be of importance, but, unfortunately, it was
impossible for us to have enough islet material for a study of this scale.
We hope that the progress made in the protocol of beta-cell differ-
entiation of human induced pluripotent stem cells soon will unlock this
limitation. In addition, we showed the interest of unbiased multi-tissue
gene expression analysis to prioritize challenging human beta-cell
investigation. Furthermore, our RNA-seq analyses of the partial
invalidation of four T2D susceptibility genes with no previously known
function in beta cell identified specific gene networks related to key
physiology pathways. When extended to other T2D susceptibility
genes, this approach may bring progress towards better patient
stratification and future precision medicine based on the genotyping of
SNPs in genes sharing same functional signatures. A recent study has
also reported the feasibility of systematic screening of T2D suscepti-
bility genes in human beta cell lines without prior step of selection on
enriched beta cell genes and suggested some plausible T2D causing
genes [32]. As different protocols have been used, the two studies
provide complementary results and guarantee that future in-depth
investigations of T2D susceptibility genes in pancreatic beta cell
should be very fruitful.
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